Skip to content
Screener

Arrowhead Research ARWR Other income, net (Note 6)

Other income, net (Note 6) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$987K+868%
ALN
Alnylam PharmaceuticalsALNY
$273K+104%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$4.42M-36.9%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-$1.7M-165%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.12B+438%
Enterprise value$12.04B+439%
P/S19.5×+15.6×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025Six Months Ended March 31, 2026Six Months Ended March 31, 2025
Interest expense(23,846)(21,639)(46,351)(43,285)
Loss on equity method investment(6,719)(6,719)
Gain on VIE's sale of IPR&D assets19,00019,000
Other, net(1,609)438(1,332)779
Total other income (expense)3,695(11,586)(8,842)(25,289)
(Loss) income before income tax expense and noncontrolling interest(137,565)369,616(109,293)194,501
Income tax expense71,753351,856
Net (loss) income including noncontrolling interest$(137,572)$367,863$(109,328)$192,645

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's other income, net (note 6)?
Arrowhead Research (ARWR) reported other income, net (note 6) of -$1.61M in Q1 2026.
How has Arrowhead Research's other income, net (note 6) changed year-over-year?
Arrowhead Research's other income, net (note 6) decreased by 467.4% year-over-year, from $438K to -$1.61M.
What is the long-term trend for Arrowhead Research's other income, net (note 6)?
Over 4 years (2021 to 2025), Arrowhead Research's other income, net (note 6) has grown at a 26.3% compound annual growth rate (CAGR), from $2.07M to $5.26M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Arrowhead Research's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude